CoChat

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.

Open access
Xu, Y., Villalona-Calero, M.A. · 2002 · Annals of Oncology

The DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.

Abstract

Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdf337

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Research works printed but not linked: 8

  1. Ilson, 1999, Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer, Proc Am Soc Clin Oncol, 18, 259a
  2. Hecht, 1998, Gastrointestinal toxicity of irinotecan, Oncology, 12, 72
  3. Prados, 2001, A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma A North American Brain Tumor Consortium (NABTC) study, Proc Am Soc Clin Oncol, 19, 162
  4. Kameyama, 2000, Activation and detoxification of CPT-11 by human lung cancer cells, Proc Am Soc Clin Oncol, 19, 505a
  5. Villalona-Calero, 2001, Pharmacologically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity, Proc Am Soc Clin Oncol, 20, 101a
  6. Kolesar, 2002, TI induction in PBMC by mitomycin-C predicts irinotecan response, Proc Am Soc Clin Oncol, 21, 115
  7. Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
  8. Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI

Cited by

See all 420

Metadata

Authors
Xu, Y., & Villalona-Calero, M. A.
Affiliations
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Corresponding author
Villalona-Calero, M.A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2002-12
Volume
13
Issue
12
Pages
1841-1851
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2112055293
Cited by
413
References
124
Citations by year
2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
FWCI
0.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Texas Health Science Center at San Antonio
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Keywords
irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
MeSH terms
Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. https://app.cochat.ai/papers/10.1093/annonc/mdf337
The paper
Xu, Y., & Villalona-Calero, M. A. (2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of Oncology. https://doi.org/10.1093/annonc/mdf337

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.